- Trials with a EudraCT protocol (676)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (31)
676 result(s) found for: Renal transplant.
Displaying page 4 of 34.
EudraCT Number: 2009-012258-19 | Sponsor Protocol Number: F506-CL-0403 | Start Date*: 2011-03-09 | |||||||||||||||||||||
Sponsor Name:Astellas Pharma Europe Ltd. | |||||||||||||||||||||||
Full Title: A Multicentre, Open-label, Pharmacokinetic Study of Modigraf® (Tacrolimus granules) in de novo Paediatric Allograft Recipients.Estudio Abierto, Multicéntrico, Farmacocinético de Modigraf® (Tacróli... | |||||||||||||||||||||||
Medical condition: De novo allograft transplantation (liver, heart, kidney) in paediatric patients. Pacientes pediátricos que reciben un trasplante de aloinjerto de novo ( hígado, corazón y riñón) | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: ES (Completed) GB (Completed) DE (Completed) BE (Completed) FR (Ongoing) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2012-004992-37 | Sponsor Protocol Number: 2012/1419 | Start Date*: 2013-02-25 |
Sponsor Name:South-Eastern Norway Regional Health Authority [...] | ||
Full Title: The effects of n-3 polyunsaturated fatty acids on glomerular filtration rate, proteinuria, fibrosis and inflammation in the kidney transplant and cardiovascular risk markers in kidney transplant re... | ||
Medical condition: Renal transplantation | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NO (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2019-002539-27 | Sponsor Protocol Number: IntraRenalTac | Start Date*: 2019-09-23 | |||||||||||
Sponsor Name:Oslo University Hospital – Rikshospitalet | |||||||||||||
Full Title: Association between intrarenal tacrolimus concentration and development of renal interstitial fibrosis in renal transplant recipients | |||||||||||||
Medical condition: Development of renal interstitial fibrosis in renal transplant recipients | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NO (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-019086-28 | Sponsor Protocol Number: AQUARIUS | Start Date*: 2011-02-21 | |||||||||||
Sponsor Name:UO Divisione Nefrologia, Dialisi e Trapianto renale | |||||||||||||
Full Title: Multicenter, no-profit, open, single sequence cross-over study on effectiveness and safety of anti-rejection therapy based on modified release Tacrolimus(Advagraf)and on patients quality of life an... | |||||||||||||
Medical condition: Kidney transplant patients | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-006162-40 | Sponsor Protocol Number: NODAT-BELATAC | Start Date*: 2013-05-28 | ||||||||||||||||
Sponsor Name:Fundació Hospital Universitari Vall d'Hebron - Institut de Recerca (VHIR) | ||||||||||||||||||
Full Title: NEW-ONSET DIABETES MELLITUS AFTER RENAL TRANSPLANTATION. A MULTICENTRE, PROSPECTIVE, RANDOMIZED, OPEN STUDY TO EVALUATE BELATACEPT-BASED VERSUS TACROLIMUS-BASED IMMUNOSUPPRESSION | ||||||||||||||||||
Medical condition: Adult kidney transplant recipients older than 45 years old with risk of developing prediabetes states after renal transplantation (PREDAT) and diabetes mellitus after renal transplantation (NODAT) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: ES (Prematurely Ended) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2008-007507-83 | Sponsor Protocol Number: CRAD001AIT12 | Start Date*: 2009-03-18 | |||||||||||
Sponsor Name:NOVARTIS FARMA | |||||||||||||
Full Title: Once-a-day regimen or Steroid withdrawal in de novo kidney transplant recipients treated with everolimus, cyclosporin and steroids: a 12-month, prospective, randomized, multicenter, open-label stud... | |||||||||||||
Medical condition: Recipients of a de novo kidney transplant. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-001042-25 | Sponsor Protocol Number: ML19199 | Start Date*: 2016-10-03 | |||||||||||
Sponsor Name:F. Hoffmann-La Roche AG | |||||||||||||
Full Title: A Study to Investigate the Impact of Pharmacogenetics on CellCept Use, in Patients Participating in a Study in Renal Transplantation | |||||||||||||
Medical condition: Renal Transplantation | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-005951-84 | Sponsor Protocol Number: | Start Date*: 2008-11-18 |
Sponsor Name:Medizinische Universität Wien, KIM III, Abteilung für Nephrologie | ||
Full Title: Treat-to-target trial of basal insulin in Post-Transplant Hyperglycemia (TIP): Efficacy and safety of a novel protocol in renal transplant recipients receiving a tacrolimus-based immunosupprerssion | ||
Medical condition: The medical condition to be investigated is post-transplant hyperglycemia in renal transplant recipients. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Completed) | ||
Trial results: View results |
EudraCT Number: 2010-018791-24 | Sponsor Protocol Number: KM003EPC | Start Date*: 2011-07-04 | |||||||||||
Sponsor Name:Kliniken der Stadt Koeln gGmbH, Klinikum Merheim | |||||||||||||
Full Title: Single-center, single-armed, open-label, prospective study assessing efficacy and safety of a conversion of stable kidney allograft recipients to an Everolimus-based regimen to prevent the developm... | |||||||||||||
Medical condition: This study is designed to assess whether a conversion from a CNI-based therapy to a CNI-free therapy with Certican® in stable renal transplant patients is able to prevent the development of Chronic... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-002092-14 | Sponsor Protocol Number: 0485-CL-E201 | Start Date*: 2008-01-21 | |||||||||||
Sponsor Name:Astellas Pharma Europe B.V. | |||||||||||||
Full Title: Efficacy and safety of Alefacept in combination with Tacrolimus, Mycophenolate Mofetil and Steroids in de-novo kidney transplantation – a multicenter, randomized, double-blind, placebo controlled, ... | |||||||||||||
Medical condition: kidney transplantation | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) NL (Completed) BE (Completed) CZ (Completed) IT (Completed) HU (Completed) DE (Completed) GB (Completed) AT (Completed) SE (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-002886-53 | Sponsor Protocol Number: PRGXLKTx-0701-TW | Start Date*: 2015-07-03 | |||||||||||
Sponsor Name:Astellas Pharma Taiwan, Inc. | |||||||||||||
Full Title: A Randomized, Open-Label, Comparative, Multi-Center Study to Assess the Safety and Efficacy of Prograf® (tacrolimus)/MMF, and Extended Release (XL) Tacrolimus /MMF in de novo Kidney Transplant Reci... | |||||||||||||
Medical condition: De novo Kidney Transplant Recipients | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-018792-17 | Sponsor Protocol Number: KM004EIC | Start Date*: 2011-07-04 | |||||||||||
Sponsor Name:Kliniken der Stadt Koeln gGmbH, Klinikum Merheim | |||||||||||||
Full Title: Single-center, single-armed, open-label, prospective study assessing efficacy and safety of a conversion of kidney allograft recipients suffering from Chronic Allograft Nephropathy (CAN) assessed ... | |||||||||||||
Medical condition: This study is designed to assess whether a conversion from a CNI-based therapy to a CNI-free therapy with Certican® and Myfortic® in renal transplant patients with Chronic Allograft Nephropathy (CA... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-000348-17 | Sponsor Protocol Number: CSL842_3001 | Start Date*: 2017-11-17 | |||||||||||
Sponsor Name:CSL Behring LLC | |||||||||||||
Full Title: A Double-blind, Randomized-Withdrawal, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Human Plasma-Derived C1-esterase Inhibitor as Add-on to Standard of Care for the Treatment of ... | |||||||||||||
Medical condition: Refractory AMR in adult renal transplant participants | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) GB (GB - no longer in EU/EEA) DE (Prematurely Ended) ES (Prematurely Ended) NL (Prematurely Ended) FR (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-001043-39 | Sponsor Protocol Number: ML17225 | Start Date*: 2016-10-03 | |||||||||||
Sponsor Name:F. Hoffmann-La Roche AG | |||||||||||||
Full Title: An Open-Label, Prospective, Randomized, Controlled, Multi-Center Study Assessing Fixed Dose Vs Concentration Controlled Cellcept Regimens For Patients Following A Single Organ Renal Transplantation... | |||||||||||||
Medical condition: Renal Transplantation | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-006652-35 | Sponsor Protocol Number: ML 20958 | Start Date*: 2007-09-28 | |||||||||||
Sponsor Name:Queen Mary University of London | |||||||||||||
Full Title: A pilot study to evaluate of the impact on bone density during treatment with mycophenolate mofetil, daclizumab in combination with ciclosporin converted to sirolimus with steroid as mainstay immun... | |||||||||||||
Medical condition: Renal Transplantation | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-002378-68 | Sponsor Protocol Number: SIRES | Start Date*: 2007-10-30 | |||||||||||
Sponsor Name:SERVICIO NEFROLOGIA HOSPITAL BELLVITGE | |||||||||||||
Full Title: Estudio piloto de Selección de la Inmunosupresión basado en un régimen basado en inhibidores de CNI o libre de CNI dependiendo de la aloreactividad donante-especifica mediante el ensayo ELISPOT en ... | |||||||||||||
Medical condition: PATIENTS THAT RECEIVE A FIRST RENAL ALLOGRAFT TRANSPLANTATION. It has been shown that the assessment of the donor specific T-cell alloimmune response can be successfully performed by using new too... | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-003987-34 | Sponsor Protocol Number: S54555 | Start Date*: 2013-03-19 | ||||||||||||||||
Sponsor Name:UZ Leuven | ||||||||||||||||||
Full Title: “Therapeutic interventions on senescence markers after human kidney transplantation, does metformine meets his expectations?” | ||||||||||||||||||
Medical condition: Kidney transplant patients 3 months after TX, with a stable kidney function, no signs of graft failure. No other conditions like heart failure, diabetes, .... | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: BE (Prematurely Ended) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2021-001520-18 | Sponsor Protocol Number: NL76839.042.21 | Start Date*: 2021-04-09 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sponsor Name:RECOVAC consortium | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Full Title: Long term efficacy and safety of SARS-CoV-2 vaccination in Dutch patients with chronic kidney disease stage G4-G5, on dialysis or after kidney transplantation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Medical condition: COVID-19 is associated with increased morbidity and mortality in kidney transplant recipients (KTR) and patients with chronic kidneydisease (CKD). Therefore, potential efficacious SARS-CoV-2 vaccin... | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial protocol: NL (Completed) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2007-005503-17 | Sponsor Protocol Number: 200710602 | Start Date*: 2011-03-31 | |||||||||||
Sponsor Name:Medizinische Hochschule Hannover | |||||||||||||
Full Title: Randomized multicenter double-blind study of phase III in patients after kidney transplantation with an acute cellular rejection with a tubulointerstinal component in kidney transplant with histolo... | |||||||||||||
Medical condition: It should be proved that additional treatment with Rituximab in patients with histologic proof of an acute cellular rejection with CD20+ lymphocytes is superior to a solitary therapy with Steroidbo... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-000925-36 | Sponsor Protocol Number: CCFZ533X2201 | Start Date*: 2015-11-26 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: A 12-month randomized, multiple dose, open-label, study evaluating safety, tolerability, pharmacokinetics/pharmacodynamics (PK/PD) and efficacy of an anti-CD40 monoclonal antibody, CFZ533, in combi... | |||||||||||||
Medical condition: acute rejection of renal transplant in de novo adult renal transplant patients | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) NL (Completed) ES (Prematurely Ended) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
